Lumos Pharma (Lumos Pharma) EBIT : $-47.48 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma EBIT?

Lumos Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-10.86 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-47.48 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lumos Pharma's annualized ROC % for the quarter that ended in Mar. 2024 was -1,252.83%. Lumos Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -7,241.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Lumos Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 2,074.09%.

Lumos Pharma EBIT Historical Data

The historical data trend for Lumos Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma EBIT Chart

Lumos Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-9.82

-26.30

-31.35

-32.04

-36.61

Lumos Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-8.04	-17.68	-8.93	-10.00	-10.86

Competitive Comparison of Lumos Pharma's EBIT

For the Biotechnology subindustry, Lumos Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's EV-to-EBIT falls into.

Lumos Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.48 Mil.

Lumos Pharma (NAS:LUMO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lumos Pharma's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-43.448 * ( 1 - 0% )	/	( (4.357	+	2.579)	/ 2 )
=	-43.448	/	3.468
=	-1,252.83 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	40.638	-	3.276	-	( 36.077	-	max(0, 7.03	-	40.035	+	36.077	))
=	4.357

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	28.078	-	2.369	-	( 23.179	-	max(0, 4.414	-	27.544	+	23.179	))
=	2.579

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Lumos Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-43.448	/	( ( (0.603 + max(-3, 0))	+	(0.534 + max(0.063000000000001, 0)) )	/	2 )
=	-43.448	/	( ( 0.603	+	0.597 )	/	2 )
=	-43.448	/	0.6
=	-7,241.33 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.748)	-	(3.276	+	0	+	3.472)
=	-3

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.184)	-	(2.369	+	0	+	1.752)
=	0.063000000000001

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lumos Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-47.476	/	-2.289
	=	2,074.09 %

Lumos Pharma EBIT Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Pharma (Lumos Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (NAS:LUMO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.lumos-pharma.com

Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Executives

David B Karpf	officer: Chief Medical Officer	1360 WILLOW ROAD #100, MENLO PARK CA 94025
Aaron Schuchart	officer: Chief Business Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S.MOPAC EXPWY,BARTONOAKSPLAZONE,#250, AUSTIN TX 78746
Es-johansson An Van	director	6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Joseph S Mccracken	director	C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Richard J Hawkins	director, officer: Chief Executive Officer	950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Emmett Cunningham	director	C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Kevin M. Lalande	director	201 WEST 5TH STREET, AUSTIN TX 78701
John C. Mckew	officer: Chief Scientific Officer	C/O LUMOS PHARMA, 4200 MARATHON BLVD, STE 200, AUSTIN TX 78756
Deerfield Mgmt Iii, L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iii, L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C)	10 percent owner, other: Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Bradley J Powers	officer: Principal Executive Officer	C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Lori D Lawley	officer: Principal Accounting Officer	C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Ernest Iii Talarico	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010